The clinical-stage biopharmaceutical firm is now recalibrating its operations to preserve capital, confirming plans to lay off 35% of its workforce. This restructuring aims to extend the company's cash runway through the third quarter of 2027, allowing management to pivot resources toward the remaining portfolio, including treatments for schizophrenia, Alzheimer’s-related agitation, and cardiometabolic disease.
In section Market Quotes
Neumora Therapeutics Halts Navacaprant Trials as Shares Plummet
Shares of Watertown-based Neumora Therapeutics shed 51% of their value Monday, cratering to 87.7 cents after the company abruptly terminated its late-stage navacaprant program. The decision follows clinical trial data showing the drug failed to reach statistical significance across primary and key secondary endpoints in two separate Phase 3 studies.
Despite the market reaction, analysts at William Blair and Mizuho characterize the selloff as an overreaction. Mizuho maintains an outperform rating with a $6 price target, arguing that the current valuation fails to account for the potential of the firm's broader drug pipeline. By abandoning navacaprant—a drug that had previously struggled in earlier evaluations—leadership hopes to clear a path toward more viable prospects.
Comments (0)
No comments yet. Be the first!